Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.
about
Factors affecting the stability and repeatability of gamma camera calibration for quantitative imaging applications based on a retrospective review of clinical dataToward preparation of antibody-based imaging probe libraries for dual-modality positron emission tomography and fluorescence imaging.Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods.Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy.Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?Cancer radioimmunotherapy.Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review.Molecular targeted α-particle therapy for oncologic applications.Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor.A novel bifunctional maleimido CHX-A'' chelator for conjugation to thiol-containing biomoleculesTarget Therapy in Hematological Malignances: New Monoclonal Antibodies.Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'.Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy ResponseAdverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.
P2860
Q30977013-79D59F4B-9D32-437A-A4AA-CAB5D389308AQ33464006-C5E6790E-C8E5-4A5F-BBCE-4C88E822E9F3Q33645793-075FCCB8-7F6A-4F3A-9F24-43A92FA8CAE5Q33768719-AD3B4335-5D1E-45C6-B59E-225A7F843AE4Q34255798-74ECD58A-B721-4395-A3AD-853E2DEAF40EQ34255894-FFA56C56-4C36-4882-A759-4282D226C15DQ34335207-37FDFDE6-F3FF-430C-B567-7A5C55ADFED4Q35070045-331EC89C-7E3C-4591-9D99-4401E24B6C1AQ35582104-B6B8E90C-387B-4363-B6EF-030CC0E1848AQ35814989-3682D7C8-79F6-4C50-81E8-72DB8D33EC3CQ35945192-C9BE20FC-2E95-4B4F-B947-9370B229E1B2Q36593424-BB9DDE28-7184-4A3B-BD91-DDF94DA77495Q36979140-8C4F636B-4B81-4F61-9D86-967A7878CE7CQ37969746-4B7B3169-9197-4E0E-82B1-7DD6BA911521Q38896113-107996D1-9431-4316-AC2E-3E67C097DCA0Q42908395-434E9C63-5B00-4DBC-824E-363F0A28D114Q50146121-68445E8C-4562-4A25-99B3-FE6E4F6A593D
P2860
Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.
@ast
Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.
@en
type
label
Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.
@ast
Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.
@en
prefLabel
Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.
@ast
Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.
@en
P1476
Tositumomab and (131)I therapy in non-Hodgkin's lymphoma
@en
P2093
Richard L Wahl
P304
P407
P478
46 Suppl 1
P577
2005-01-01T00:00:00Z